# US 2024/0197720 A1 · Bupropion dosage forms with reduced food and alcohol dosing effects

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197720 A1
- Document ID: US20240197720A1
- Status: Published application
- Kind: A1
- Application number: 18/590,452
- Filed: 2024-02-28
- Published: 2024-06-20
- Earliest claimed: 2022-06-30
- Assignees: Antecip Bioventures II LLC
- Applicants: Antecip Bioventures II LLC
- Inventors: Herriot Tabuteau
- Web page: https://patentgrep.com/patent/US20240197720A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

## Claims

### Claim 1

A method of treating agitation associated with Alzheimer's disease, comprising: 1) selecting a human patient having agitation associated with Alzheimer's disease who is receiving a dosage form twice a day and is consuming alcohol; and 2) advising the human patient to minimize, but not abruptly discontinue, alcohol consumption;
wherein the dosage form comprises 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion, 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan, and a polymer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the human patient is an adult male, and the human patient consumes two servings or less of alcohol per day after the human patient is advised to minimize alcohol consumption.

### Claim 3 (depends on 1)

The method of claim 1, wherein the human patient is an adult female, and the human patient consumes one serving or less of alcohol per day after the human patient is advised to minimize alcohol consumption.

### Claim 4 (depends on 1)

The method of claim 1, wherein the dosage form further comprises colloidal silicon dioxide.

### Claim 5 (depends on 1)

The method of claim 1, wherein the dosage form further comprises crospovidone.

### Claim 6 (depends on 1)

The method of claim 1, wherein the dosage form further comprises: glyceryl monocaprylocaprate.

### Claim 7 (depends on 1)

The method of claim 1, wherein the dosage form further comprises L-cysteine hydrochloride monohydrate.

### Claim 8 (depends on 1)

The method of claim 1, wherein the dosage form further comprises magnesium stearate.

### Claim 9 (depends on 1)

The method of claim 1, wherein the dosage form further comprises microcrystalline cellulose.

### Claim 10 (depends on 1)

The method of claim 1, wherein the dosage form further comprises polyvinyl alcohol.

### Claim 11 (depends on 1)

The method of claim 1, wherein the dosage form further comprises sodium lauryl sulfate.

### Claim 12 (depends on 1)

The method of claim 1, wherein the dosage form further comprises stearic acid.

### Claim 13 (depends on 1)

The method of claim 1, wherein the dosage form further comprises titanium dioxide.

### Claim 14 (depends on 1)

The method of claim 1, wherein the polymer is a carbomer homopolymer.

### Claim 15 (depends on 1)

The method of claim 1, wherein the dosage form further comprises: colloidal silicon dioxide, crospovidone, glyceryl monocaprylocaprate, L-cysteine hydrochloride monohydrate, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol, red iron oxide, sodium lauryl sulfate, stearic acid, talc, titanium dioxide, or yellow iron oxide, or a combination thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein the dosage form comprises 105 mg of bupropion hydrochloride.

### Claim 17 (depends on 1)

The method of claim 1, wherein the dosage form comprises 45 mg of dextromethorphan hydrobromide.

### Claim 18 (depends on 16)

The method of claim 16, wherein the dosage form comprises 45 mg of dextromethorphan hydrobromide.

### Claim 19 (depends on 1)

The method of claim 1, wherein the dextromethorphan is formulated for immediate release.

### Claim 20 (depends on 19)

The method of claim 19, wherein the bupropion is formulated for extended release.

### Claim 21 (depends on 1)

The method of claim 1, wherein the dosage form is administered orally.

### Claim 22 (depends on 1)

The method of claim 1, wherein the dosage form has reduced alcohol dosing effects as compared with administering twice a day the same amount of the bupropion alone.
